Innovata plc and Baxter Healthcare Corporation's ADEPT® Adhesion Reduction Solution for use in gynecological laparoscopic procedures in the United States, has been recently approved by the USFDA.

ADEPT®, a 4% icodextrin solution (been used for adhesion reduction in Europe since 2000) is indicated for use intraperitoneally as an adjunct to good surgical technique for the reduction of post-surgical adhesions in patients undergoing gynecological laparoscopic adhesiolysis.

Adhesions are abnormal attachments between tissues or organs and gynecological adhesions may cause pain, secondary infertility or other complications in women.

"This is a significant development for patients with adhesion-related disorders and the surgeons who are managing those patients," said Thomas Lyons, MD, of Atlanta, GA, who served as one of the clinical investigators for the U.S. trials.

"This is currently the only product which has approval for laparoscopic use, making it doubly helpful since laparoscopic surgery is a better solution for adhesions than traditional open surgery. As a gynecologic surgeon who works in this area I am excited for our patients and look forward to improved outcomes for our patients."

ADEPT®, a liquid (can be delivered directly and rapidly to the site through a laparoscopic port during surgery), is the first and only approved fluid-based approach for adhesion reduction in gynecological laparoscopic adhesiolysis in the United States. It was developed by Innovata and licensed to Baxter on a global basis and will be launched in the United States by Baxter's BioSurgery business in the fourth quarter of the year.

Read more at Baxter Healthcare Corporation.